36 VCs and 3 funds investing in Drug Discovery
Partner
Lux Capital
Check: No verified personal or standard Lux check-size range is published. Tess invests at both early and growth stages and participates in Lux company creation; founders should confirm round fit directly rather than infer an allocation from fund size or disclosed company rounds.
Tess is a technically trained generalist investing where AI, biology, aerospace, and the physical world intersect. She seeks engineers and scientists turning frontier research into companies, with particular interest in computational methods that make biology more engineerable, the data and model bottlenecks behind scientific discovery, and high-consequence systems such as biodefense.
Investor Relations Director
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Rachelle Young as Investor Relations Director. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Senior Associate ESG and Impact
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Elisa Camorani as Senior Associate ESG and Impact. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Vice President Finance | Funds
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Cyril Lesser as Vice President Finance | Funds. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Venture Partner
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Arnoud Dijkstra as Venture Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Chief Compliance Officer & Legal Affairs
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Machteld Groeneveld as Chief Compliance Officer & Legal Affairs. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Managing Partner
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Oskar Slotboom as Managing Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
General Partner
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Daniela Couto as General Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Manager Secretarial Services
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Olga Ziessen as Manager Secretarial Services. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Head of Investor Relations
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Robbert van de Griendt as Head of Investor Relations. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Venture Partner
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Wouter Verhoeven as Venture Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Principal
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Rianne Ellenbroek as Principal. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Senior Advisor
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies John J.P. Kastelein as Senior Advisor. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
AML/KYC Manager
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Patricia Vonk as AML/KYC Manager. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Vice President Finance
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Jennifer Fritzsche as Vice President Finance. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Head of Impact and ESG
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Silva Dezelan as Head of Impact and ESG. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Associate
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Karen Chan as Associate. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Executive Assistant
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Dragana Dragusin as Executive Assistant. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Venture Partner
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Elena Ritsou as Venture Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Paralegal
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Maureen Wouters as Paralegal. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Venture Partner
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Rob de Ree as Venture Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Managing Partner
V-Bio Ventures
Check: V-Bio does not publish a standard current startup check-size range on its official site.
The official roster identifies Christina Takke as Managing Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.
Partner
V-Bio Ventures
Check: V-Bio does not publish a standard current startup check-size range on its official site.
The official roster identifies Katja Rosenkranz as Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.
Finance Manager
V-Bio Ventures
Check: V-Bio does not publish a standard current startup check-size range on its official site.
The official roster identifies Martin Solleveld as Finance Manager. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Venture Partner
V-Bio Ventures
Check: V-Bio does not publish a standard current startup check-size range on its official site.
The official roster identifies Mathias Falcenberg as Venture Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.
Managing Partner
V-Bio Ventures
Check: V-Bio does not publish a standard current startup check-size range on its official site.
The official roster identifies Shelley Margetson as Managing Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.
Partner
V-Bio Ventures
Check: V-Bio does not publish a standard current startup check-size range on its official site.
The official roster identifies Ward Capoen as Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.
Managing Partner
V-Bio Ventures
Check: V-Bio does not publish a standard current startup check-size range on its official site.
The official roster identifies Willem Broekaert as Managing Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.
Founding Partner
i&i Bio
Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.
Karel Kubias, MBA invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.
Founding Partner
i&i Bio
Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.
Ivan Vohlmuth invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.
Partner
i&i Bio
Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.
Barbora Šumová, Ph.D. invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.
Founding Partner
i&i Bio
Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.
Tomáš Maršálek, MBA invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.
Partner
i&i Bio
Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.
Dr. Anela Vukoja invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.
Advisor
i&i Bio
Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.
Magdalena Marciniak, Ph.D. is listed in a Advisor capacity at i&i Bio. The firm does not publish a person-specific investment mandate for this role; the firm's strategy is included only as shared organizational context.
Associate
i&i Bio
Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.
Pavlína Koutecká invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.
Office Manager
i&i Bio
Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.
Simona Šandová is listed in a Office Manager capacity at i&i Bio. The firm does not publish a person-specific investment mandate for this role; the firm's strategy is included only as shared organizational context.